PTU-associated cutaneous vasculitis with ANCA anti-MPO and anti-PR3 antibodies

Netherlands Journal of Medicine

Volumn 61, Issue 9, 2003, Pages 296-299

  Jacobs, E M G ^a,c   Hartkamp, A ^b   Kaasjager, H A H ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; LORATADINE; MYELOPEROXIDASE; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; PROTEINASE 3 ANTIBODY; THIAMAZOLE; UNCLASSIFIED DRUG; MYELOBLASTIN; SERINE PROTEINASE;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD VESSEL INJURY; CASE REPORT; CYTOTOXICITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; GRAVES DISEASE; HUMAN; HUMAN TISSUE; LEUKOCYTE ACTIVATION; NEUTROPHIL; PLASMAPHERESIS; RELAPSE; SINUSITIS; SKIN BIOPSY; SKIN DEFECT; URTICARIA; VASCULITIS; ALLERGIC VASCULITIS; BIOPSY; BLOOD; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; PURPURA;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOPSY; FEMALE; GRAVES DISEASE; HUMANS; MYELOBLASTIN; PROPYLTHIOURACIL; PURPURA; SERINE ENDOPEPTIDASES; VASCULITIS, ALLERGIC CUTANEOUS;

EID: 1542573461     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
2. Segelmark M, Westman K, Wieslander J. How and why should we detect ANCA? Clin Exp Rheumatol 2000;18:629-35.
3. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405-13.
4. Khurshid I, Sher J. Disseminated intravascular coagulation and vasculitis during propylthiouracil therapy. Postgrad Med J 2000;76:185-6.
5. Mathieu E, Fain O, Sitbon M, Thomas M. Systemic adverse effect of antithyroid drugs. Clin Rheumatol 1999;18:66-8.
6. Vasily DB, Tyler WB. Propylthiouracil-induced cutaneous vasculitis. Case presentation and review of the literature. JAMA 1980;243:458-61.
7. Harper L, Cockwell P, Savage CO. Case of propylthiouracil-induced ANCA associated small vessel vasculitis. Nephrol Dial Transplant 1998;13:455-8.
8. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
9. Chastain MA, Russo GG, Boh EE, Chastain JB, Falabella A, Millikan LE. Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature. J Am Acad Dermatol 1999;41:757-64.
10. Lam DC, Lindsay RH. Accumulation of 2-14Cpropylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979;28:2289-96.
11. Kitahara T, Hiromura K, Maezawa A, et al. Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. Clin Nephrol 1997;47:336-40.
12. Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999;84:13-6.
13. Griswold WR, Mendoza SA, Johnston W. Vasculitis associated with propylthiouracil. Evidence for immune complex pathogenesis and response to therapy. West J Med 1978;128:543-6.
14. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J 2000;47:467-70.
15. Jiang X, Khursigara G, Rubin R. Transformation of lupus inducing drugs to cytotoxic products by activated neutrophils. Science 1994;266:810.
16. Wolf D, Ben-Yehuda A, Okon E, Naparstek Y. Nodular vasculitis associated with propylthiouracil therapy. Cutis 1992;49:253-5.
17. Harper L, Savage CO. Leukocyte-endothelial interactions in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Rheum Dis Clin North Am 2001;27:887-903.
18. Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1993;3:305-9.
19. Cohen Tervaert J, Tel W, Vries O de, Links T, Stegeman C. The occurrence of anti-neutrophil cytoplasmic antibodies (ANCA) with specifity for proteinase 3 (PR3), myeloperoxidase (MPO) and/or elastase (HLE) during treatment with antithyreoid drugs. Sarcoidosis vasculitis and diffuse lung diseases: official journal of WASOG (World Association of Sarcoidosis and Other Granulomatous Disorders) 1996;13:280.
20. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000;142:587.
21. Sera N, Ashizawa K, Ando T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595-9.
22. Choi HK, Merkel PA, Tervaert JW, Black RM, McCluskey RT, Niles JL. Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis Rheum 1999,42:384-8.
23. Noh JY, Asari T, Hamada N, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf) 2001;54:651-4.
24. Goldberg EI, Shoji T, Sapadin AN. Henoch-Schonlein purpura induced by clarithromycin. Int J Dermatol 1999;38:706-8.
25. Gavura SR, Nusinowitz S. Leukocytoclastic vasculitis associated with clarithromycin. Ann Pharmacother 1998;32:543-5.
26. Vega T de, Blanco S, Lopez C, Pascual E, Sanchez M, Zamarron A. Clarithromycin-induced leukocytoclastic vasculitis. Eur J Clin Microbiol Infect Dis 1993;12:563-5.
27. Otsuka S, Kinebuchi A, Tabata H, Yamakage A, Yamazaki S. Myeloperoxicase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy. Br J Dermatol 2000;142:828-30.
28. Stone O. Proliferative ioderma: a possible mechanism. Int J Dermatol 1985;24:565-6.